RxDoctor Payments DataLook up a doctor →

Alan Kanouff, DO

Pulmonary Disease · Altoona, PANPI 1487787131

Payments from drug & device makers

$809,484in general payments, 2019–2025

Across 1,839 payments — averaging $440.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$530K
  • GSK$179K
  • Eisai Inc.$19K
  • Verona Pharma, Inc.$19K
  • Amgen$18K
  • Mylan Specialty L.p.$17K
  • plus $28K from 47 others

What the payments were for

  • Consulting fees$7,9841%
  • Speaking & faculty fees$719,64189%
  • Travel & lodging$45,3956%
  • Food & beverage$35,8524%
  • Education$6110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$809,484 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$248,697
Medicare patients
554
Services billed
2,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter850$646,717
GlassiaAlpha-1-Proteinase Inhibitor39$443,959
TezspireTezepelumab-Ekko54$243,328
XywavSodium,calcium,mag,pot Oxybate11$162,800
Breztri AerosphereBudesonide/Glycopyr/Formoterol181$145,403
Dupixent PenDupilumab36$129,834
Fasenra PenBenralizumab17$95,651
NucalaMepolizumab12$51,403
Breo ElliptaFluticasone/Vilanterol101$48,510
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$27,137
Spiriva RespimatTiotropium Bromide48$23,650
Tadalafil20$21,908
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$21,025
Roflumilast206$18,965
Fluticasone-SalmeterolFluticasone Propion/Salmeterol106$17,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$179,453$797,2761,084 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$307$443,95939 claims
AstraZenecaTezspire, Breztri Aerosphere, Daliresp, Symbicort, Airsupra$529,883$408,061292 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$984$44,67479 claims
MerckDulera$193$14,68648 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$33$4,57212 claims
Eisai Inc.Dayvigo$18,798$3,98212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →